Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis

Conclusion Overall, despite the older age and a greater number of patients with high-risk category (including Philadelphia chromosome-positive) in the hyper-CVAD group, this did not translate into a difference in survival outcome between the 2 groups. The hyper-CVAD regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. Micro-Abstract Several induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). We show that the hyper-CVAD (hyper fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. The combination of tyrosine kinase inhibitors for Philadelphia chromosome-positive (+) patients and rituximab for CD20+ patients were significantly more frequent in the hyper-CVAD arm and might have affected outcomes favorably. There is still a need for large, prospective, randomized studies to establish the best induction regimen for adult ALL patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research